Recent data, from BIA and Clarivate, has revealed that investment in UK biotech continues to be strong.
Recent data, published by the BioIndustry Association (BIA) and Clarivate, has revealed that investment in biotech companies in the United Kingdom continues to be strong with companies raising more than £1 billion (US $1.3 billion) in equity finance between June and August 2020.
A notable investment highlighted from the report includes the raising of £119 million (US $154 million) by Freeline Therapeutics—a clinical-stage gene therapy company—on the initial public offering on NASDAQ. Additionally, venture capital funding has returned to pre-COVID-19 levels, reaching £283 million (US $364 million) in the second quarter of 2020.
“In a year where COVID-19 has caused major disruptions to the global economy it is fantastic to see the strong investment picture for UK biotech continue to gather pace,” said Steve Bates OBE, CEO of the BIA, in an Oct. 12, 2020 press release. “During the pandemic, UK biotech has shown its strategic value and received great interest from UK based investors, with many investing in the sector for the first time. This could be transformative for patients and the economy, and for shareholders, when combined with the global money we already attract—large pharma, US, and Chinese venture capitalists are already aware of the vast opportunities UK biotech presents.”
Source: BIA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.